NCT00958334View on ClinicalTrials.gov

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 7, 2006

Primary Completion Date

October 15, 2008

Study Completion Date

October 15, 2008

Conditions
Uterine Fibroids
Interventions
DRUG

Proellex®

25 mg daily (two 12.5 mg capsules)

Trial Locations (11)

29201

SC Clinical Research Center, Columbia

33607

Insignia Clinical Research (Tampa Bay Women's Center), Tampa

77030

Advances in Health Inc., Houston

77054

Obstetrical & Gynecolgical Associates, PA (OGA), Houston

80218

Downtown Women's Health Care, Denver

85015

Women's Health Research, Phoenix

85032

Arizona Wellness Centre for Women, Phoenix

89128

Affiliated Clinical Research, Inc., Las Vegas

92108

Medical Centre for Clinical Research, San Diego

92123

Women's Health Care, Inc., San Diego

98105

Women's Clinical Research Centre, Seattle

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT00958334 - Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 | Biotech Hunter | Biotech Hunter